Do not use a solution that does not clear
Multi-stimuli-responsive platforms may improve selectivity, with added structural complexity, difficult release characterization and higher analytical burden during translation [48, 60,61,62,63]
But coverage is more nuanced than a yes-no decision. Insurers may respond to lower GLP-1 prices by increasing restrictions, which are already stringent, as Klebanoff showed in two studies with LDI Senior Fellows Jalpa Doshi and Judith Long, and colleagues
Figure 4 shows that discontinuation rates for SGLT2 inhibitors differed little between subgroups of patients by status of ASCVD, chronic kidney disease and heart failure, although some of the differences were statistically significant
Hu, Y., Meng, X., Zhang, F., Xiang, Y
Its use in a clinical setting should be discussed with a licensed provider who can assess appropriateness and ensure quality sourcing